Table 5.

Associations of post-finasteride-treatment 5α-androstane-3α,17β-diol glucuronide, sex steroid hormones, and sex hormone binding globulin with prostate cancer risk

Overall cancerGleason Score 2–6Gleason Score 7–10Gleason Score 8–10
Range of valuesN case/controlOR (95% CI)bN case/controlOR (95% CI)bN case/controlOR (95% CI)bN case/controlOR (95% CI)b
3α-dGa, ng/mL<(1.0)135/164Ref.82/164Ref.49/164Ref.15/164Ref.
(1.0) to <(1.4)127/1710.89 (0.63–1.24)78/1710.88 (0.60–1.30)45/1710.88 (0.55–1.40)11/1710.70 (0.31–1.58)
(1.4) to <(2.1)137/1700.99 (0.71–1.38)78/1700.90 (0.61–1.33)54/1701.11 (0.71–1.75)17/1701.14 (0.54–2.40)
≥ (2.1)130/1690.96 (0.68–1.34)64/1690.74 (0.49–1.11)60/1691.28 (0.82–2.00)25/1691.81 (0.91–3.60)
Pslope0.960.180.170.04
Testosterone, ng/dL<(318)137/168Ref.76/168Ref.55/168Ref.19/168Ref.
(318) to <(398)132/1690.94 (0.67–1.32)71/1690.87 (0.58–1.30)58/1691.10 (0.71–1.72)16/1690.94 (0.46–1.94)
(398) to <(494)120/1680.83 (0.58–1.19)71/1680.82 (0.54–1.25)45/1680.86 (0.53–1.40)15/1680.92 (0.43–1.98)
≥ (494)139/1691.11 (0.75–1.64)83/1691.06 (0.66–1.68)50/1691.14 (0.67–1.94)18/1691.38 (0.60–3.15)
Pslope0.840.920.920.52
Free testosterone, ng/dL<(7.3)138/168Ref.72/168Ref.62/168Ref.24/168Ref.
(7.3) to <(9.1)138/1700.95 (0.68–1.33)77/1700.97 (0.65–1.44)54/1700.89 (0.58–1.38)12/1700.55 (0.26–1.16)
(9.1) to <(11.)146/1691.09 (0.78–1.51)94/1691.26 (0.85–1.86)50/1690.90 (0.58–1.40)16/1690.83 (0.41–1.65)
≥ (11.2)106/1670.83 (0.59–1.19)58/1670.81 (0.53–1.24)42/1670.81 (0.51–1.30)16/1670.91 (0.45–1.83)
Pslope0.510.690.400.92
Estrone, pg/mL<(39.4)109/167Ref.56/167Ref.47/167Ref.11/167Ref.
(39.4) to <(49.0)139/1671.27 (0.90–1.78)79/1671.37 (0.91–2.07)57/1671.24 (0.79–1.94)23/1672.19 (1.03–4.67)
(49.0) to <(59.2)128/1711.19 (0.84–1.68)78/1711.41 (0.93–2.13)47/1711.01 (0.64–1.61)14/1711.28 (0.56–2.93)
≥ (59.2)145/1621.54 (1.09–2.17)84/1621.74 (1.15–2.63)55/1621.35 (0.85–2.13)20/1622.11 (0.97–4.59)
Pslope0.030.010.350.21
Total estradiol, pg/mL<(29.1)121/169Ref.72/169Ref.44/169Ref.14/169Ref.
(29.1) to <(35.2)117/1681.04 (0.74–1.47)58/1680.86 (0.57–1.31)53/1681.31 (0.82–2.08)17/1681.33 (0.63–2.81)
(35.2) to <(42.4)122/1621.15 (0.81–1.62)72/1621.15 (0.77–1.72)46/1621.18 (0.73–1.90)16/1621.26 (0.59–2.70)
≥ (42.4)167/1711.49 (1.07–2.07)98/1711.45 (0.98–2.13)65/1711.62 (1.03–2.56)21/1711.64 (0.79–3.41)
Pslope0.020.030.060.22
Free estradiol, pg/mL<(0.77)124/170Ref.69/170Ref.49/170Ref.14/170Ref.
(0.77) to <(0.92)106/1670.89 (0.63–1.26)61/1670.93 (0.62–1.41)41/1670.86 (0.53–1.38)14/1671.02 (0.47–2.23)
(0.92) to <(1.14)145/1621.33 (0.95–1.86)80/1621.35 (0.91–2.02)60/1621.35 (0.87–2.11)21/1621.65 (0.80–3.38)
≥ (1.14)152/1711.34 (0.96–1.87)90/1711.44 (0.97–2.14)58/1711.28 (0.81–2.00)19/1711.47 (0.70–3.07)
Pslope0.020.020.110.18
  • a5α-androstane-3α,17β-diol glucuronide.

  • bAdjusted for age, race, family history of prostate cancer, SHBG, body mass index, and serum cholesterol.